Abstracts Archive - Page 2410 of 2425 - ACR Meeting Abstracts

Abstract Number: 181 • 2012 ACR/ARHP Annual Meeting
Thiopurine S-Methyltransferase Levels in Patients with Behçet’s Disease
Hakan Emmungil¹, Melike Kalfa², Raika Durusoy³, Figen Yargucu Zihni², Gokhan Keser⁴ and Kenan Aksu², ¹Rheumatology, Mersin State Hospital, Mersin, Turkey, ²Dept. of Internal Medicine, Division of Rheumatology, Ege University, Dept. of Internal Medicine, Division of Rheumatology, Ege University, Izmir, Turkey, ³Department of Public Health, Ege University, Department of Public Health, Ege University, Izmir, Turkey, ⁴Dept. of Internal Medicine, Division of Rheumatology, Ege University School of Medicine, Izmir, Turkey
Background/Purpose: Azathioprine (AZA) is an immunosuppressive agent which is widely used not only for the treatment of Behcet’s disease (BD), but also for the treatment…
Abstract Number: 182 • 2012 ACR/ARHP Annual Meeting
Comprehensive Analysis of Protein Expression in Peripheral Blood Mononuclear Cells From Patients with Behcet’s Disease
Takuya Yoshioka¹, Manae Kurokawa², Yukiko Takakuwa¹, Hiromasa Nakano¹, Seido Ooka³, Nobuko Iizuka², Toshiyuki Sato², Mitsumi Arito², Kouhei Nagai⁴, Kazuki Okamoto², Naoya Suematsu², Noboru Suzuki⁵, Shoichi Ozaki⁶ and Tomohiro Kato², ¹Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Dept of Biochemistry, St. Marianna Univ School Med, Kawasaki, Japan, ³St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Kinki Univ., Kinokawa, Japan, ⁵Department of Immunology and Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁶Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: To elucidate the pathophysiology of Behcet’s disease (BD) and to establish biomarkers for the disease, we comprehensively analyzed protein expression of peripheral blood mononuclear…
Abstract Number: 183 • 2012 ACR/ARHP Annual Meeting
A Strong Association Between HLA-A*26 and Behçet’s Syndrome in Japanese Patients: From Two-Center Cohort Study of Behçet’s Syndrome
Tatsuo Kobayashi¹, Mitsumasa Kishimoto², Kazuki Yoshida¹, Yuri Ohara³, Hiroto Nakano¹, Masahiro Minoda¹, Hideto Oshikawa¹ and Kazuo Matsui¹, ¹Rheumatology, Kameda Medical Center, Kamogawa City, Chiba, Japan, ²Division of Allergy and Rheumatology, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, ³Allergy and Rheumatology, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan
Background/Purpose: An association between Behçet’s Syndrome (BS) and HLA-B*51 is widely reported among many different ethnic groups. Recently, a few reports from Taiwan, Greece and…
Abstract Number: 184 • 2012 ACR/ARHP Annual Meeting
The Retrospective Review of 39 Intestinal Behcet’s Disease Focusing On the Requirement for the Immunosuppresive Drugs Other Than Corticosteroid
Yoshitaka Kimura¹, Kurumi Asako², Hirotoshi Kikuchi², Akiteru Takeuchi³ and Hajime Kono², ¹Department of Internal Medicine, Teikyo University school of medecine, Tokyo, Japan, ²Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³6-7-8 Arakawa, Tokyo, Japan
Background/Purpose: To examine the demography, clinical characteristics, features of intestinal lesions, treatment, and prognosis in patients with the intestinal Behcet’s disease currently followed at a…
Abstract Number: 185 • 2012 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Tumour Necrosis Factor Antagonists for Patients with Behçet’s Disease with Uveitis As Main Involvement
M. Victoria Hernández¹, Marina Mesquida², Gerard Espinosa³, Victor Llorens², Laura Pelegrin², Juan D. Cañete⁴, Ricard Cervera⁵, Alfredo M. Adan² and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Ophthalmology, Hospital Clínic of Barcelona, Barcelona, Spain, ³Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Spain, ⁴Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ⁵Autoimmune Diseases, Hospital Clínic of Barcelona, Barcelona, Spain
Background/Purpose: To assess the long-term efficacy and safety of tumour necrosis factor (TNF) antagonists (infliximab [IFX], adalimumab [ADA] and golimumab) for the treatment of patients…
Abstract Number: 186 • 2012 ACR/ARHP Annual Meeting
Long-Term Infliximab Therapy in Patients with Behcet’s Disease Is Well Tolerated without Increasing Risk of Serious Infections
Sho Ueda, Hiroshi Tsukamoto, Yasushi Inoue, Masahiro Ayano, Satomi Hisamoto, Naoko Ueki, Atsushi Tanaka, Shun-ichiro Ohta, Naoyasu Ueda, Yojiro Arinobu, Hiroaki Niiro, Takahiko Horiuchi and Koichi Akashi, Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose: Infliximab (IFX) is a monoclonal antibody against tumor necrosis factor-a (TNF-a) and is increasingly used in various immune-related diseases including rheumatoid arthritis (RA), ankylosing…
Abstract Number: 147 • 2012 ACR/ARHP Annual Meeting
Improvements in Long-Term Health-Related Quality of Life in Chronic Gout Patients Refractory to Conventional Therapies Treated with Pegloticase: Results From Responder Cohort
Dinesh Khanna¹, Puja Khanna² and Faith D. Ottery³, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Division of Rheumatology/Dept. of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, ³Medical Affairs, Savient Pharmaceuticals, Inc., East Brunswick, NJ
Background/Purpose: In replicate, 6-month, randomized, placebo-controlled Phase 3 clinical trials a subgroup of patients with treatment-refractory chronic gout (RCG) who received pegloticase infusions (8 mg)…
Abstract Number: 148 • 2012 ACR/ARHP Annual Meeting
Towards a Preliminary Definition of Remission From Gout
William Taylor¹, Nicola Dalbeth², Jasvinder A. Singh³, Kenneth G. Saag⁴ and H. R. Schumacher⁵, ¹University of Otago, Wellington, New Zealand, ²Medicine, University of Auckland, Auckland, New Zealand, ³Department of Medicine, University of Alabama, Tuscaloosa, AL, ⁴Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ⁵Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA
Background/Purpose: There is currently no agreed criterion for remission in chronic gout. The aim of this study was to develop a preliminary definition for remission…
Abstract Number: 149 • 2012 ACR/ARHP Annual Meeting
Natural Language Processing in the Evaluation of Gout Quality Indicators
Gail S. Kerr¹, J. Steuart Richards², Carl A. Nunziato³, Olga V. Patterson⁴, Scott L. DuVall⁵, David D. Maron⁶ and Richard L. Amdur⁷, ¹Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ²Rheumatology, Washington DC VA and Georgetown University, Washington, DC, ³Rheumatology, Washington DC VA and Howard University, Washington, DC, ⁴VA Salt Lake City Health Care System and University of Utah School of Medicine, UT, ⁵VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ⁶Research Department, Washington DC VA Medical Center, Washington, DC, ⁷Washington DC VA and Georgetown Unviversity, Washington, DC
Background/Purpose: Gout is a common inflammatory arthritis with significant impact on both patients and health care systems. Despite ACR/EULAR management guidelines and gout quality indicators…
Abstract Number: 150 • 2012 ACR/ARHP Annual Meeting
Ulodesine (BCX4208) Long-Term Safety When Added to Allopurinol in the Chronic Management of Gout: A Phase 2 24-Week Blinded Safety Extension and Vaccine Challenge Study
Alan S. Hollister¹, Andreas Maetzel¹, Michael A. Becker², Robert Terkeltaub³, David Fitz-Patrick⁴, Valerie Smith⁵ and William P. Sheridan⁶, ¹Development, BioCryst Pharmaceuticals, Inc., Durham, NC, ²Medicine, University of Chicago, Chicago, IL, ³Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ⁴East-West Medical Research Institute, Honolulu, HI, ⁵Pharpoint Research, Inc., Durham, NC, ⁶BioCryst Pharmaceuticals, Inc., Durham, NC
Background/Purpose: A majority of gout patients treated with 300 mg/d allopurinol do not reach the therapeutic goal range serum uric acid concentration (sUA) of 4…
Abstract Number: 151 • 2012 ACR/ARHP Annual Meeting
Management of Gout Attacks in the Community
Tuhina Neogi¹, Clara Chen², Christine E. Chaisson², David J. Hunter³, Hyon Choi⁴ and Yuqing Zhang⁵, ¹Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ²Boston University School of Public Health, Boston, MA, ³Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ⁴Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: We previously examined management of gout attacks in the community in 2003-4. Since then, new agents have become available and gout publications have increased,…
Abstract Number: 152 • 2012 ACR/ARHP Annual Meeting
Rilonacept for Gout Flare Reduction: Estimation of Number Needed to Treat to Benefit (NNTB)
Robert R. Evans¹, Steven P. Weinstein², George D. Yancopoulos³ and Yuhwen Soo⁴, ¹Clinical Sciences, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ²Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ³Research Labs, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Two similarly designed phase 3 randomized clinical trials (PRESURGE-1 and PRESURGE-2) in gout patients initiating urate-lowering therapy (ULT) showed that subcutaneous treatment with the…
Abstract Number: 153 • 2012 ACR/ARHP Annual Meeting
Prevention of Recurrent Calcium Stones in Subjects with Hyperuricosuria: A Randomized Controlled Trial of Febuxostat Vs Allopurinol
David S. Goldfarb¹, Patricia A. MacDonald², Lhanoo Gunawardhana³, Solomon Chefo³ and Lachy McLean⁴, ¹New York Universtiy Langone Medical Center, New York, NY, ²Takeda Pharmaceuticals USA, Inc., Deerfield, IL, ³Takeda Global Research & Development Center, Inc., Deerfield, IL, ⁴Takeda Global Research & Development Center, Inc, Deerfield, IL
Background/Purpose: About one-third of patients with recurrent calcium oxalate (CaOx) stones have hyperuricosuria as a urinary risk factor. Febuxostat (FEB), a newer xanthine oxidase inhibitor…
Abstract Number: 154 • 2012 ACR/ARHP Annual Meeting
Dual-Energy Computed Tomography As a Diagnostic Tool for Gout During Intercritical Periods
Gabriel S. Breuer¹, Naama Bogot² and Gideon Nesher³, ¹Rheumatology, Shaare Zedek Medical Center, Jerusalem, Israel, ²Radiology, Shaare Zedek Medical Center p o box 3235 Jerusalem, Israel, Israel, ³Internal Medicine, Shaare Zedek Medical Center, Jerusalem, Israel
Background/Purpose: Dual-energy computed tomography (DECT) is a sensitive method for identifying uric acid deposits in joints and periarticular soft tissues in patients suspected of having…
Abstract Number: 155 • 2012 ACR/ARHP Annual Meeting
Accuracy of International Classification of Disease Codes for Calcium Pyrophosphate Disease in the Veterans Adminstration Healthcare System
Karri A. Huber¹, Lawrence M. Ryan² and Ann K. Rosenthal³, ¹Rheumatology, MCW Froedtert Hospital, Milwaukee, WI, ²Department of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ³Div of Rheumatology, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Calcium pyrophosphate disease (CPPD) commonly affects elderly patients, but few advances in our management of this disease have occurred in the 50 years since…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].